drugset / Trial / NCT00626860
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
Phase 1/2
Completed
20 enrolled
Beth Israel Deaconess Medical Center
Genzyme, a Sanofi Company · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.
Timeline
- Start
- 2000-07
- Primary completion
- 2002-01
- Completion
- 2008-09-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC/tumor fusion vaccine | Vaccine | — | Subcutaneous |